Aida Pharmaceuticals (AIDA)

[PaperProphet]

Yes, it looks like the income tax benefit was about $0.03/share out of the $0.08. Even discounting that, the earnings were really good.

I'm not sure what to think about the Rh-APO2L drug. Six months or so ago they said they would release the phase II results within a month. If they actually did release those results, I don't know where they are--I assumed it would be in a press release but that wasn't the case.

The quarterly report says that the R&D expense for the period was mainly for costs incurred for phase II of Rh-APO2L and preparation for phase III so that gives some indication to the situation there.